First National Advisers LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

First National Advisers LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 39.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,969 shares of the medical research company’s stock after purchasing an additional 554 shares during the period. Thermo Fisher Scientific makes up about 1.5% of First National Advisers LLC’s holdings, making the stock its 11th biggest holding. First National Advisers LLC’s holdings in Thermo Fisher Scientific were worth $999,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Thermo Fisher Scientific by 168.1% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,014,472 shares of the medical research company’s stock valued at $1,094,244,000 after buying an additional 1,262,989 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Thermo Fisher Scientific by 394.8% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,110,504 shares of the medical research company’s stock worth $563,237,000 after purchasing an additional 886,075 shares in the last quarter. Jennison Associates LLC raised its holdings in Thermo Fisher Scientific by 416.0% in the 2nd quarter. Jennison Associates LLC now owns 651,227 shares of the medical research company’s stock worth $353,799,000 after purchasing an additional 525,014 shares in the last quarter. First Trust Advisors LP raised its holdings in Thermo Fisher Scientific by 278.0% in the 1st quarter. First Trust Advisors LP now owns 395,802 shares of the medical research company’s stock worth $233,780,000 after purchasing an additional 291,089 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Thermo Fisher Scientific by 203.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 417,572 shares of the medical research company’s stock worth $246,639,000 after purchasing an additional 279,838 shares in the last quarter. 85.92% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $11.24 during trading on Wednesday, reaching $569.48. 394,897 shares of the company traded hands, compared to its average volume of 1,950,869. The firm has a 50 day simple moving average of $556.73 and a 200-day simple moving average of $547.95. The company has a quick ratio of 1.22, a current ratio of 1.74 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $223.35 billion, a PE ratio of 32.64, a P/E/G ratio of 2.11 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 52-week low of $475.77 and a 52-week high of $618.35.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its quarterly earnings results on Wednesday, October 26th. The medical research company reported $5.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.78 by $0.30. The firm had revenue of $10.68 billion for the quarter, compared to the consensus estimate of $9.86 billion. Thermo Fisher Scientific had a net margin of 15.92% and a return on equity of 22.97%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.04 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, January 16th. Stockholders of record on Thursday, December 15th were issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date of this dividend was Wednesday, December 14th. Thermo Fisher Scientific’s payout ratio is presently 6.75%.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Thursday, November 10th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

TMO has been the subject of several research reports. SVB Leerink upped their price objective on shares of Thermo Fisher Scientific from $555.00 to $620.00 and gave the stock an “outperform” rating in a report on Friday, January 6th. Benchmark downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Thursday, October 27th. StockNews.com started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, October 12th. They issued a “buy” rating on the stock. Citigroup reduced their target price on shares of Thermo Fisher Scientific from $715.00 to $650.00 and set a “buy” rating on the stock in a research report on Thursday, October 27th. Finally, Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating on the stock in a research report on Tuesday, January 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $633.30.

Insider Activity

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 200 shares of the company’s stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $561.39, for a total transaction of $112,278.00. Following the completion of the sale, the director now directly owns 979 shares of the company’s stock, valued at $549,600.81. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Debora L. Spar sold 200 shares of the firm’s stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $561.39, for a total value of $112,278.00. Following the transaction, the director now directly owns 979 shares of the company’s stock, valued at approximately $549,600.81. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 8,200 shares of the business’s stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $487.45, for a total value of $3,997,090.00. Following the sale, the chief executive officer now directly owns 178,005 shares of the company’s stock, valued at approximately $86,768,537.25. The disclosure for this sale can be found here. Insiders have sold a total of 31,475 shares of company stock valued at $16,073,443 in the last 90 days. 0.43% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.